Insight Molecular Diagnostics (IMDX) Return on Sales (2020 - 2026)

Insight Molecular Diagnostics has reported Return on Sales for 7 years, with the latest figure at 3.51% in Q1 2026.

• Quarterly Return on Sales fell 348.0% year-over-year to 3.51% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.26% (down 12.0% YoY) and the FY2025 annual result came in at 0.15%, up 52.0% from the prior year.
• Return on Sales declined to 3.51% in Q1 2026 per IMDX's latest filing, from 0.21% in the prior quarter.
• Over five years, Return on Sales peaked at 0.02% in Q4 2023 and troughed at 3.51% in Q1 2026.
• A 5-year average of 0.47% and a median of 0.21% in 2025 frame the typical range for Return on Sales.
• The sharpest annual moves came in 2023 and 2026: Return on Sales soared 105 bps in 2023, then tumbled 348 bps in 2026.
• Over 5 years, Return on Sales stood at 0.08% in 2022, then jumped by 76 bps to 0.02% in 2023, then tumbled by 1072 bps to 0.23% in 2024, then rose by 9 bps to 0.21% in 2025, then slumped by 1584 bps to 3.51% in 2026.
• According to Business Quant data, Return on Sales over the past three periods registered 3.51%, 0.21%, and 0.29% for Q1 2026, Q4 2025, and Q3 2025 respectively.